Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
Improving outcomes in PDAC appears to depend not only on therapeutic innovation, but also on more consistent delivery of timely, biomarker-informed, multidisciplinary, and equitable care.
HCC management continues to be constrained by surveillance underutilization, delayed diagnosis, inconsistent multidisciplinary care, treatment heterogeneity, and regional disparities, highlighting the need for risk-stratified, systems-level implementation beyond guideline dissemination alone.
Colon cancer outcomes depend on effective care delivery; navigation, outreach, multidisciplinary care, molecular profiling, and structured surveillance may improve survival and equity
This review synthesizes real-world evidence showing that disparities, diagnostic and staging gaps, and uneven implementation of modern therapies continue to compromise outcomes across the cutaneous melanoma care continuum.
Persistent gaps in HPV vaccination, cervical cancer screening, triage, follow-up, and surveillance continue to challenge equitable prevention and better outcomes worldwide.
A global review of leukemia care gaps, highlighting delays, undertreatment, non-adherence, and monitoring inequities that limit real-world outcomes
Persistent gaps in detection, staging, biomarker testing, perioperative care, and treatment access continue to constrain outcomes in gastric and GEJ adenocarcinoma.
Undertreatment in prostate cancer represents a multifaceted challenge characterized by disparities in care delivery, underutilization of definitive and intensified therapies, and incomplete integration of evidence-based, biomarker-guided treatment strategies across disease stages.
Globally, hepatocellular carcinoma is the leading liver cancer subtype, characterized by high fatality, marked regional heterogeneity, male predominance, and changing risk factor profiles.
HPV is strongly linked to cervical and other cancers worldwide, highlighting the importance of vaccination, screening, and surveillance.
Cutaneous melanoma is an increasingly prevalent skin cancer with marked geographic variation, significant mortality burden, and preventable risk factors worldwide.
Lung cancer remains a leading global cause of death, with declining rates in some regions but rising cases, shifting histology, disparities, and prevention challenges.
Prostate cancer shows major global disparities: high-income regions overdetect indolent disease, while low-resource settings face late diagnosis, higher mortality, and survivorship burdens.
Colorectal cancer burden remains high worldwide, with regional disparities, rising early-onset cases, and prevention centered on risk reduction and screening.
HPV drives a major global cancer burden through persistent oncogenic infection, shaping epidemiology, prevention, screening, and treatment strategies.
Leukemia imposes a substantial global burden, with evolving mortality, survival, disability, and quality-of-life patterns across subtypes and populations.
This review summarizes global gastric cancer epidemiology, trends, subtype patterns, and prevention strategies, highlighting regional disparities and screening implications.
Global pancreatic cancer burden is rising; prevention, early detection, and targeted surveillance are key to improving outcomes and reducing mortality.
siRNA therapeutics have prompted specialized regulatory frameworks addressing their unique mechanisms, manufacturing, and safety, shaping clinical development, monitoring, and therapeutic use.
Accelerated oncology approvals speed access via surrogate endpoints, but withdrawal rates, delayed confirmatory trials, and expanding coordination expose evidentiary risks.